Mark van Duin - Concepedia

Author

Mark van Duin

Also Known As

M Duin, M Van Duin, M van Duin, M. Van Duin, M. Van Duin, M. van Duin, Mark Van Duin, Mark van Duin, Mark van Duin, van Duin, Mark

150

Publications

Citations

H-Index

Concepts

All Affiliations

Erasmus MC Erasmus MC Cancer Institute Vrije Universiteit Amsterdam Erasmus University Rotterdam University Medical Center Utrecht

About

Mark van Duin is an author at Erasmus MC specializing in medicine, pathology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	2K
2	Cell Biology	5	5	1.1K
3	Public Health	3	3	419
4	Engineering	1	1	64
5	Health Sciences	1	1	16

Mark van Duin

Publications

4.2K

Citations

H-Index

Page 1

	Year	Citations
A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia Stefan Gröschel, Mathijs A. Sanders, Remco M. Hoogenboezem, Cell ChromatinGeneticsGata2 DeregulationCancer GeneticsGene Expression	2014	696
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma Inger S. Nijhof, Tineke Casneuf, Jeroen van Velzen, Blood	2016	371
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients Annemiek Broyl, Dirk Hose, Henk M. Lokhorst, Blood	2010	336
A gene expression signature for high-risk multiple myeloma Rowan Kuiper, Annemiek Broyl, Yvonne de Knegt, Leukemia Hematological MalignancyTumor BiologyGene Expression SignatureMedicineMixed-phenotype Acute Leukemia	2012	297
Human papillomavirus 16 load in normal and abnormal cervical scrapes: An indicator of CIN II/III and viral clearance Mark van Duin, Peter J.F. Snijders, Henri F.J. Schrijnemakers, International Journal of Cancer PathologyGynecologyCytopathologyCancer-associated VirusHuman Papillomavirus Vaccines	2002	258
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial Annemiek Broyl, Sophie L. Corthals, Joost L.M. Jongen, The Lancet Oncology Hematological MalignancyNeuro-oncologyPeripheral NeuropathyMedicineHematology	2010	220
The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape Madelon M.E. de Jong, Zoltán Kellermayer, Natalie Papazian, Nature Immunology InflammationHematological MalignancyMultiple Myeloma MicroenvironmentImmunologyHematology	2021	215
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma Christie P.M. Verkleij, Marloes E.C. Broekmans, Mark van Duin, Blood Advances	2021	153
Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. Peter J.F. Snijders, Mark van Duin, Jan M.M. Walboomers, PubMed Telomerase ActivityPathologyGynecologyHtert MrnaTumor Biology	1998	131
High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance Annemiek Broyl, Rowan Kuiper, Mark van Duin, Blood	2012	128

Page 1